Alexion Pharmaceuticals Stock News

These drugmakers have cornered the markets they need in order to flourish in the long term.

Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.

The short interest data are out for September 15, the most recent settlement date.

Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.

This coming weak is likely to be bearish but is also likely to be the end of the September decline.

Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.

BOSTON & BORDENTOWN, N.J.--(BUSINESS WIRE)--Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

BOSTON--(BUSINESS WIRE)--Alexion to Discuss Key Pipeline Programs at Virtual Investor Day

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

The short interest data are out for August 31, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential u

The market indexes pulled back significantly in the past week, with the NASDAQ 100 ETF losing 11% from its September high to its low this week.

Although markets have pulled back so far in September, many are viewing this as a technical correction, as the markets ran very hot in a very strong August.

BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting.

If getting a good deal is your thing, you're going to love these bargains.